Company intelligence / Profile preview
Sania Therapeutics
London, England, United Kingdomsaniarx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Sania Therapeutics has demonstrated in-vivo proof of concept for its gene therapy platform targeting dysfunctional neural circuits. The lead program addresses severe spasticity—a prevalent disorder with high unmet need—and additional undisclosed programs are underway. No clinical trial results yet; all disclosed assets are preclinical or earlier.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- AAV-based gene therapyGene therapyNeuromodulation using conditionally activated ion channels
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Sania Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sania Therapeutics.